腹腔注射氟比洛芬酯对大鼠骨癌痛的影响  

EFFECTS OF INTRAPERITONEAL INJECTION OF FLURBIPROFEN AXETIL ON OF BONE CANCER PAIN IN RATS

作　　者：胡正权[1] 杨许丽[1] 马正良[1] 顾小萍[1] 

机构地区：[1]南京大学医学院附属鼓楼医院麻醉科,南京210008

出　　处：《中国疼痛医学杂志》2013年第8期478-484,共7页Chinese Journal of Pain Medicine

基　　金：南京市卫生局课题(Ykk10062)

摘　　要：目的:探讨腹腔注射氟比洛芬酯对大鼠骨癌痛的影响。方法:30只雌性SD大鼠,完全随机分为5组(n=6):肿瘤+生理盐水组(C组)、肿瘤+氟比洛芬酯10 mg kg-1 d-1组(CK10组)、肿瘤+氟比洛芬酯25 mg kg-1 d-1组(CK25组)、肿瘤+氟比洛芬酯50 mg kg-1 d-1组(CK50组)和假手术组+生理盐水(sham组)。大鼠胫骨接种肿瘤14 d后,腹腔分别注射相应剂量氟比洛芬酯及生理盐水,每天两次,连续7 d。于造模前、后3、5、7、10 d及14、17、21 d给药前、后半小时测量左后足底机械性缩足阈值(paw mechanical withdrawal threshold,PMWT)和行走痛行为评分。结果:在14、17、21 d给药后,与C组(2.67±1.03,2.13±0.96,1.73±0.43)相比,CK25组(5.00±1.10,6.00±1.26,6.33±0.82)、CK50组(6.67±1.03,7.00±1.10,7.67±1.51)大鼠PMWT明显增加(P<0.05);与C组(2.17±0.41,2.50±0.55,3.33±0.52)相比,CK25组(1.50±0.55,1.33±0.52,1.50±0.55)、CK50(1.10±0.63,1.17±0.41,1.00±0.63)大鼠行走痛评分显著减少(P<0.05);CK10组PMWT(3.60±0.89)和行走痛评分(2.50±0.55)与C组比较在d21差异有统计学意义(P<0.05)。在17、21 d给药前,与C组比较,CK25组(5.33±1.03,6.33±0.82)和CK50组(5.67±0.82,7.00±1.10)PWMT值明显延长(P<0.05),CK50组(1.67±0.52,2.00±0.63)行走痛评分明显降低(P<0.05);CK25组(2.17±0.41)行走痛评分在d 21显著减少(P<0.05)。结论:在大鼠骨癌痛模型中,腹腔注射氟比洛芬酯可以剂量依存性缓解骨癌痛,镇痛效果持久。Objective： To investigate the effect of flurbiprofen axetil by intraperitoneal injection on bone cancer pain in rats. Methods： Thirty female Sprague Drawley （SD） rats were randomly divided into 5 groups （ n = 6 in each ）： cancer ＋ normal saline group （C）, cancer ＋ flurbiprofen axetil 10 mgokg-1 .d-1 group （CK10）, cancer ＋ flurbiprofen axetil 25 mg.kg-1.d-1 group （CK25）, cancer ＋ flurbiprofen axetil 50 mg.kg-1.d-1 group （CK50）, sham operation ＋ normal saline group （sham）. Flurbiprofen axetil or normal saline was administered intraperitoneally twice daily for seven days from Day 14 to Day 21 following cancer inoculation in rat tibia. The paw mechanical withdrawal threshold （PMWT） was measured and the ambulatory pain was graded before modeling and at post-operative day 3, 5, 7 and 10, as well as at day 14, 17 and 20, prior to and half an hour following drug or normal saline administration. Results： At day 14, 17 and 21, after the administration of flurbiprofen axetil, PMWTs in CK25 （5.00 ± 1.10, 6.00± 1.26, 6.33±0.82） and CK50 groups （6.67±1.03, 7.00＋ 1.10, 7.67± 1.51） were significantly increased （P 〈 0.05） compared with C group （2.67±1.03, 2.13±0.96, 1.73±043）; Scores of ambulatory pain in CK25 group （1.50±0.55, 1.33±0.52, 1.50 _ 0.55） and CK50 group （1.10 ±0.63, 1.17 ± 0.41, 1.00 ±0.63） were significantly reduced （P 〈 0.05 ） compared with C group （ 2.17 ± 0.41, 2.50 ± 0.55, 3.33± 0.52 ） . The differences in PMWT and the ambulatory pain score were statistically significant between CK10 group （3.60±0.89, 2.50±0.55） and C group at day 21 （P 〈 0.05 ） . The PMWT value was significantly prolonged （P 〈 0.05 ） in CK25 （ 5.33± 1.03, 6.33±0.82 ） and CK50 （ 5.67±0.82, 7.00±1.10 ） groups compared with C group before drug administration at day 17 and 21, and the ambulatory pain score was significantly reduced （P 〈 0.05 ） in CK50 group （ 1.67±0.52, 2.00±0.63 ） , which was also obser

关 键 词：骨癌痛 氟比洛芬酯 触诱发痛 痛觉过敏 大鼠 

分 类 号：R738.1[医药卫生—肿瘤]